IOVA · Company research
Iovance Biotherapeutics, Inc. (IOVA): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
24records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar | The article highlights two medical stocks with positive Earnings Surprise Prediction (ESP) metrics that could potentially beat their upcoming earnings reports. Idexx Laboratories (IDXX) holds a #2 Buy rating with a +0.59% ESP ahead of its November 2, 2026 earnings release, while Iovance Biotherapeutics (IOVA) has a #3 Hold rating with a +22.22% ESP before reporting on November 5, 2026. Both stocks show promise for positive earnings surprises based on the Zacks ESP methodology. | View source ↗ | Zacks Investment Research | Oct 20, 2026 | bullish | 1 | 1 |
| IOVA Stock Has Gained More Than 21% In Four Sessions, And Barclays Sees Another 52% Upside Potential - Here’s Why - Stocktwits | IOVA Stock Has Gained More Than 21% In Four Sessions, And Barclays Sees Another 52% Upside Potential - Here’s Why Stocktwits | View source ↗ | Stocktwits | Oct 17, 2026 | neutral | 0 | 0.6 |
| Barclays lifts target for Iovance Biotherapeutics stock to USD 18.00 - ad-hoc-news.de | Barclays lifts target for Iovance Biotherapeutics stock to USD 18.00 ad-hoc-news.de | View source ↗ | ad-hoc-news.de | Oct 15, 2026 | neutral | 0 | 0.6 |
| IOVA Stock: Can Cell Therapy Deliver Commercial Growth for Iovance? - CMC Markets | IOVA Stock: Can Cell Therapy Deliver Commercial Growth for Iovance? CMC Markets | View source ↗ | CMC Markets | Oct 14, 2026 | neutral | 0 | 0.6 |
| Why Did IOVA Stock Gain Pre-Market Today? - Stocktwits | Why Did IOVA Stock Gain Pre-Market Today? Stocktwits | View source ↗ | Stocktwits | Oct 14, 2026 | neutral | 0 | 0.6 |
| IOVA Stock Fundamentals & Key Ratios - Pluang | IOVA Stock Fundamentals & Key Ratios Pluang | View source ↗ | Pluang | Oct 11, 2026 | neutral | 0 | 0.6 |
| Why Is IOVA Stock Falling Today? - Stocktwits | Why Is IOVA Stock Falling Today? Stocktwits | View source ↗ | Stocktwits | Oct 9, 2026 | neutral | 0 | 0.6 |
| How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings | The article explains the Zacks Earnings ESP (Expected Surprise Prediction) tool, which identifies stocks likely to beat earnings estimates by comparing the most accurate analyst estimates to consensus estimates. When combined with a Zacks Rank #3 or better, this approach has historically resulted in positive surprises 70% of the time with ~28% average annual returns. Two medical stocks highlighted as examples are Iovance Biotherapeutics (IOVA) with a +22.22% ESP and Gilead Sciences (GILD) with a +2.18% ESP, both positioned to potentially beat their upcoming earnings reports. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 1 | 1 |
| How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings | The article explains the Zacks Earnings ESP (Expected Surprise Prediction) tool, which identifies stocks likely to beat earnings estimates by comparing the most accurate analyst estimates to consensus estimates. When combined with a Zacks Rank #3 or better, this approach has historically resulted in positive surprises 70% of the time with ~28% average annual returns. Two medical stocks highlighted as examples are Iovance Biotherapeutics (IOVA) with a +22.22% ESP and Gilead Sciences (GILD) with a +2.18% ESP, both positioned to potentially beat their upcoming earnings reports. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 1 | 1 |
| IOVA Stock Hits Fresh 52-Week Peak On UBS Target Hike, Melanoma Sector Optimism - Stocktwits | IOVA Stock Hits Fresh 52-Week Peak On UBS Target Hike, Melanoma Sector Optimism Stocktwits | View source ↗ | Stocktwits | Oct 9, 2026 | neutral | 0 | 0.6 |
| IOVA Stock Pulls Back As Traders Eye Biotech Momentum - StocksToTrade | IOVA Stock Pulls Back As Traders Eye Biotech Momentum StocksToTrade | View source ↗ | StocksToTrade | Oct 6, 2026 | neutral | 0 | 0.6 |
| Why Iovance Biotherapeutics (IOVA) Stock Is Down Today - Quiver Quantitative | Why Iovance Biotherapeutics (IOVA) Stock Is Down Today Quiver Quantitative | View source ↗ | Quiver Quantitative | Oct 6, 2026 | neutral | 0 | 0.6 |
| Top 3 Health Care Stocks That May Collapse In Q4 - Benzinga | Top 3 Health Care Stocks That May Collapse In Q4 Benzinga | View source ↗ | Benzinga | Oct 5, 2026 | neutral | 0 | 0.6 |
| Iovance: Buy Now Before Many Growth Catalysts Kick In (NASDAQ:IOVA) - Seeking Alpha | Iovance: Buy Now Before Many Growth Catalysts Kick In (NASDAQ:IOVA) Seeking Alpha | View source ↗ | Seeking Alpha | Oct 5, 2026 | neutral | 0 | 0.6 |
| Iovance Biotherapeutics (IOVA) Stock Gets Fair Value Boost On Amtagvi Demand And Margin Outlook - Yahoo Finance | Iovance Biotherapeutics (IOVA) Stock Gets Fair Value Boost On Amtagvi Demand And Margin Outlook Yahoo Finance | View source ↗ | Yahoo Finance | Oct 3, 2026 | neutral | 0 | 0.6 |
| These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar | The article highlights two medical stocks with positive Earnings Surprise Prediction (ESP) metrics that could outperform expectations: Align Technology (ALGN) with a +1.23% ESP ahead of October 28 earnings, and Iovance Biotherapeutics (IOVA) with a +22.22% ESP before November 5 earnings. Both stocks hold a Zacks Rank #3 (Hold) rating, and positive ESP combined with favorable rankings historically produce positive surprises 70% of the time. | View source ↗ | Zacks Investment Research | Oct 2, 2026 | bullish | 1 | 1 |
| These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar | The article highlights two medical stocks with positive Earnings Surprise Prediction (ESP) metrics that could outperform expectations: Align Technology (ALGN) with a +1.23% ESP ahead of October 28 earnings, and Iovance Biotherapeutics (IOVA) with a +22.22% ESP before November 5 earnings. Both stocks hold a Zacks Rank #3 (Hold) rating, and positive ESP combined with favorable rankings historically produce positive surprises 70% of the time. | View source ↗ | Zacks Investment Research | Oct 2, 2026 | bullish | 1 | 1 |
| Iovance Biotherapeutics (NasdaqGM:IOVA) Stock Forecast & Analyst Predictions - Simply Wall Street | Iovance Biotherapeutics (NasdaqGM:IOVA) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Oct 2, 2026 | neutral | 0 | 0.6 |
| Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer | Iovance Biotherapeutics announced the appointment of Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer effective September 30, 2026. Berkowitz brings extensive experience in global drug development and cell therapy from previous roles at Arvinas Pharmaceuticals and Bristol Myers Squibb, where he led clinical strategies resulting in FDA approvals for CAR-T cell therapies and other treatments. He will lead Iovance's TIL platform development across multiple solid tumor cancers. | View source ↗ | GlobeNewswire Inc. | Oct 1, 2026 | bullish | 1 | 1 |
| IOVA Stock Hits 52-Week High on Raised Revenue Outlook for 2026 - Yahoo Finance | IOVA Stock Hits 52-Week High on Raised Revenue Outlook for 2026 Yahoo Finance | View source ↗ | Yahoo Finance | Sep 30, 2026 | neutral | 0 | 0.6 |
| IOVA Stock Hits 52-Week High on Raised Revenue Outlook for 2026 - The Globe and Mail | IOVA Stock Hits 52-Week High on Raised Revenue Outlook for 2026 The Globe and Mail | View source ↗ | The Globe and Mail | Sep 30, 2026 | neutral | 0 | 0.6 |
| Nearly 60% revenue growth is implied by Iovance's 2026 forecast. - Stock Titan | Nearly 60% revenue growth is implied by Iovance's 2026 forecast. Stock Titan | View source ↗ | Stock Titan | Sep 29, 2026 | neutral | 0 | 0.6 |
| Iovance Biotherapeutics (IOVA) Stock Trades At A Premium As Shares Jumped 421% - Simply Wall Street | Iovance Biotherapeutics (IOVA) Stock Trades At A Premium As Shares Jumped 421% Simply Wall Street | View source ↗ | Simply Wall Street | Sep 27, 2026 | neutral | 0 | 0.6 |
| IOVA Stock Hits New 52-Week High As Shares Jump 14% — What Drove The Rally? - TradingView | IOVA Stock Hits New 52-Week High As Shares Jump 14% — What Drove The Rally? TradingView | View source ↗ | TradingView | Aug 19, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.